BACKGROUND: Breast cancer occurs rarely in men. To the authors' knowledge, no population-based estimates of the incidence of human epidermal growth factor receptor 2 (HER2)-positive breast cancer or of the distribution of breast cancer subtypes among male breast cancer patients have been published to date. Therefore, the objective of the current study was to explore breast tumor subtype distribution by race/ethnicity among men in the large, ethnically diverse population of California. METHODS: This study included men who were diagnosed with invasive breast cancer between 2005 and 2009 with known estrogen receptor (ER) and progesterone receptor (PR) (together, hormone receptor [HR]) status and HER2 status reported to the California Cancer Registry. Among the men with HR-positive tumors, survival probabilities between groups were compared using log-rank tests. RESULTS: Six hundred six patients were included. The median age at diagnosis was 68 years. Four hundred ninety-four men (81.5%) had HR-positive tumors (defined as ER-positive and/or PR-positive and HER2-negative). Ninety men (14.9%) had HER2-positive tumors, and 22 (3.6%) had triple receptor-negative (TN) tumors. Among the patients with HR-positive tumors, non-Hispanic black men and Hispanic men were more likely to have PR-negative tumors than non-Hispanic white men. No statistically significant differences in survival were observed according to tumor subtype (P = .08). Differences in survival according to race/ethnicity were observed among all patients (P = .087) and among those with HR-positive tumors (P = .0170), and non-Hispanic black men had poorer outcomes. CONCLUSIONS: In this large, representative cohort of men with breast cancer, the distribution of tumor subtypes was different from that reported for women and varied by patient race/ethnicity. Non-Hispanic black men were more likely to have TN tumors and ER-positive/PR-negative tumors than white men.
BACKGROUND:Breast cancer occurs rarely in men. To the authors' knowledge, no population-based estimates of the incidence of human epidermal growth factor receptor 2 (HER2)-positive breast cancer or of the distribution of breast cancer subtypes among male breast cancerpatients have been published to date. Therefore, the objective of the current study was to explore breast tumor subtype distribution by race/ethnicity among men in the large, ethnically diverse population of California. METHODS: This study included men who were diagnosed with invasive breast cancer between 2005 and 2009 with known estrogen receptor (ER) and progesterone receptor (PR) (together, hormone receptor [HR]) status and HER2 status reported to the California Cancer Registry. Among the men with HR-positive tumors, survival probabilities between groups were compared using log-rank tests. RESULTS: Six hundred six patients were included. The median age at diagnosis was 68 years. Four hundred ninety-four men (81.5%) had HR-positive tumors (defined as ER-positive and/or PR-positive and HER2-negative). Ninety men (14.9%) had HER2-positive tumors, and 22 (3.6%) had triple receptor-negative (TN) tumors. Among the patients with HR-positive tumors, non-Hispanic black men and Hispanic men were more likely to have PR-negative tumors than non-Hispanic white men. No statistically significant differences in survival were observed according to tumor subtype (P = .08). Differences in survival according to race/ethnicity were observed among all patients (P = .087) and among those with HR-positive tumors (P = .0170), and non-Hispanic black men had poorer outcomes. CONCLUSIONS: In this large, representative cohort of men with breast cancer, the distribution of tumor subtypes was different from that reported for women and varied by patient race/ethnicity. Non-Hispanic black men were more likely to have TN tumors and ER-positive/PR-negative tumors than white men.
Authors: Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan Journal: JAMA Date: 2006-06-07 Impact factor: 56.272
Authors: Mariana Chavez-Macgregor; Jennifer Litton; Huiqin Chen; Sharon H Giordano; Clifford A Hudis; Antonio C Wolff; Vicente Valero; Gabriel N Hortobagyi; Melissa L Bondy; Ana Maria Gonzalez-Angulo Journal: Cancer Date: 2010-09-01 Impact factor: 6.860
Authors: Larissa A Korde; Jo Anne Zujewski; Leah Kamin; Sharon Giordano; Susan Domchek; William F Anderson; John M S Bartlett; Karen Gelmon; Zeina Nahleh; Jonas Bergh; Bruno Cutuli; Giancarlo Pruneri; Worta McCaskill-Stevens; Julie Gralow; Gabriel Hortobagyi; Fatima Cardoso Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: H Stalsberg; D B Thomas; K A Rosenblatt; L M Jimenez; A McTiernan; A Stemhagen; W D Thompson; M G Curnen; W Satariano; D F Austin Journal: Cancer Causes Control Date: 1993-03 Impact factor: 2.506
Authors: Marília C A Machado; Natalia M Ocarino; Rogéria Serakides; Ludmila R Moroz; Angelo Sementilli; Karine A Damasceno; Claudia H Cruz; Alessandra Estrela-Lima Journal: J Vet Diagn Invest Date: 2020-01-10 Impact factor: 1.279
Authors: Robert Foerster; Lars Schroeder; Frank Foerster; Volker Wulff; Birgit Schubotz; Dieter Baaske; Christian Rudlowski Journal: Breast Care (Basel) Date: 2014-04 Impact factor: 2.860
Authors: José Pablo Leone; Bernardo Amadeo Leone; Ariel O Zwenger; Carlos Teodoro Vallejo; Alberto Omar Romero; Mario Raúl Machiavelli; Juan Eduardo Pérez; Julieta Leone Journal: Breast Cancer Res Treat Date: 2021-01-03 Impact factor: 4.872
Authors: Louise A Brinton; Tim J Key; Laurence N Kolonel; Karin B Michels; Howard D Sesso; Giske Ursin; Stephen K Van Den Eeden; Shannon N Wood; Roni T Falk; Dominick Parisi; Chantal Guillemette; Patrick Caron; Véronique Turcotte; Laurel A Habel; Claudine J Isaacs; Elio Riboli; Elisabete Weiderpass; Michael B Cook Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544
Authors: Julieta Leone; Rachel A Freedman; Nancy U Lin; Sara M Tolaney; Carlos T Vallejo; Bernardo A Leone; Eric P Winer; José Pablo Leone Journal: Breast Cancer Res Treat Date: 2021-03-26 Impact factor: 4.872
Authors: Suleiman Alfred Massarweh; George W Sledge; Dave P Miller; Debbie McCullough; Valentina I Petkov; Steven Shak Journal: J Clin Oncol Date: 2018-03-27 Impact factor: 44.544